MediWound Ltd. (NASDAQ:MDWD) Given Average Rating of "Hold" by Brokerages

Key Points

• Analysts give MediWound an average rating of "Hold" from five analysts (1 sell, 1 hold, 3 buy) with an average 1‑year price target of $31.67, though recent downgrades include Wall Street Zen to "strong sell" and Weiss Ratings' "sell (d-)".
• Financially, shares trade near $16.81 with a market cap of $216M; the company reported Q4 EPS of -$0.56 on $1.87M revenue and analysts forecast about -2.66 EPS for the current fiscal year, reflecting negative margins and ROE.
• Institutional investors own about 46.83% of the stock, and several funds (Sphera, Russell, Barclays, Squarepoint and others) recently increased or initiated positions.

Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) have earned an average recommendation of "Hold" from the five analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $31.6667.

Several analysts have recently weighed in on MDWD shares. Wall Street Zen lowered shares of MediWound from a "hold" rating to a "strong sell" rating in a research report on Saturday, March 7th. Weiss Ratings restated a "sell (d-)" rating on shares of MediWound in a research note on Thursday, January 22nd.

MediWound Trading Up 3.8%

Shares of NASDAQ MDWD opened at $16.81 on Friday. The firm has a market capitalization of $216.01 million, a price-to-earnings ratio of -8.00 and a beta of 0.15. MediWound has a one year low of $14.14 and a one year high of $22.50. The business has a fifty day simple moving average of $17.25 and a 200 day simple moving average of $17.80.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.The business had revenue of $1.87 million for the quarter. On average, research analysts anticipate that MediWound will post -2.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Sphera Funds Management LTD. grew its position in MediWound by 24.3% in the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company's stock valued at $4,252,000 after acquiring an additional 45,077 shares during the period. Kotler Kevin acquired a new position in MediWound during the fourth quarter worth $6,225,000. Russell Investments Group Ltd. lifted its holdings in shares of MediWound by 45.1% during the fourth quarter. Russell Investments Group Ltd. now owns 3,653 shares of the biopharmaceutical company's stock valued at $67,000 after acquiring an additional 1,135 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of MediWound in the 4th quarter valued at $297,000. Finally, Barclays PLC boosted its stake in shares of MediWound by 32.5% in the 4th quarter. Barclays PLC now owns 15,276 shares of the biopharmaceutical company's stock valued at $282,000 after purchasing an additional 3,747 shares in the last quarter. Institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.